Company to present on its ongoing Phase 1
ovarian cancer CAR-T trial
SAN
JOSE, Calif., Oct. 31,
2023 /PRNewswire/ -- Anixa Biosciences,
Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a
biotechnology company focused on the treatment and prevention of
cancer, today announced that it will present at the Ovarian Cancer
National Conference taking place from November 1 – 3, 2023.
The presentation, entitled "Infusion of Autologous T Cells
Engineered to Target FSH Receptor in Recurrent Ovarian Cancer - A
Phase 1 Clinical Trial" will be presented by Dr. Pamela Garzone, Anixa's Chief Development
Officer; and will discuss the clinical development of Anixa's novel
chimeric antigen receptor T-cell (CAR-T) therapy for ovarian
cancer.
"We are pleased to be presenting at the Ovarian Cancer National
Conference," said Dr. Amit Kumar,
Chairman and CEO of Anixa Biosciences. "We look forward to
providing an overview of our Phase 1 ovarian cancer trial to an
audience which is highly interested in new therapies to battle
ovarian cancer."
The Ovarian Cancer National Conference is organized by the
Ovarian Cancer Research Alliance ("OCRA"). OCRA is the leading
organization in the world fighting ovarian cancer from all fronts
while supporting women and their families. The organization has
invested $100 million in ovarian
cancer research, educated 95,000 medical professionals, and
advocated for $200 million in
government research and education funding.
About Anixa Biosciences, Inc.
Anixa is a
clinical-stage biotechnology company focused on the treatment and
prevention of cancer. Anixa's therapeutic portfolio consists of an
ovarian cancer immunotherapy program being developed in
collaboration with Moffitt Cancer Center, which uses a novel type
of CAR-T, known as chimeric endocrine receptor T-cell (CER-T)
technology. The Company's vaccine portfolio includes a novel
vaccine being developed in collaboration with Cleveland Clinic to
prevent breast cancer – specifically triple negative breast cancer
(TNBC), the most lethal form of the disease – as well as a vaccine
to prevent ovarian cancer. These vaccine technologies focus on
immunizing against "retired" proteins that have been found to be
expressed in certain forms of cancer. Anixa's unique business model
of partnering with world-renowned research institutions on clinical
development allows the Company to continually examine emerging
technologies in complementary fields for further development and
commercialization. To learn more, visit www.anixa.com or
follow Anixa on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Statements that are not
historical fact may be considered forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are not statements of historical
facts, but rather reflect Anixa's current expectations concerning
future events and results. We generally use the words "believes,"
"expects," "intends," "plans," "anticipates," "likely," "will" and
similar expressions to identify forward-looking statements. Such
forward-looking statements, including those concerning our
expectations, involve risks, uncertainties and other factors, some
of which are beyond our control, which may cause our actual
results, performance or achievements, or industry results, to be
materially different from any future results, performance, or
achievements expressed or implied by such forward-looking
statements. These risks, uncertainties and factors include, but are
not limited to, those factors set forth in "Item 1A - Risk Factors"
and other sections of our most recent Annual Report on Form 10-K as
well as in our Quarterly Reports on Form 10-Q and Current Reports
on Form 8-K. We undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.
You are cautioned not to unduly rely on such forward-looking
statements when evaluating the information presented in this press
release.
Contacts:
Stephen
Kilmer
Investor Relations
skilmer@anixa.com
646-274-3580
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download
multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-to-present-at-the-ovarian-cancer-research-alliance-ocra-ovarian-cancer-national-conference-301972345.html
SOURCE Anixa Biosciences, Inc.